speb/financial-data huggingface dataset:
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 14780000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 14780000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -1077068000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -24702000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: 632172000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Change In Payable: 361874000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -241805000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -349529000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 114893000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Common Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 6443872000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 6443872000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 429295000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 429295000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 1355478000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 176785000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Current Assets: 6900078000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 6900078000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Current Debt: 1095244000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 1095244000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 1095244000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 1095244000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 3653008000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 3653008000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 8470000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 8470000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Depreciation: 38161000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 38161000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 38161000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 13411000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 38161000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 13411000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 19165690.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 19004000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Diluted EPS: 20.14
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.42
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 385997000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 14810000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 3654000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 3654000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — EBIT: 505280000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — EBIT: 29339000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — EBITDA: 543441000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — EBITDA: 42750000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — End Cash Position: 888992000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -21301000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 3138683000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 3138683000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 96610000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: 10354000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 78910000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 71822000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 71822000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 1036498000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 1036498000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 3058174000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 3058174000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Gross Profit: 2293604000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 342892000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Interest Expense: 104838000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 13659000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 104838000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 13659000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Interest Income: 35886000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 35886000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -104838000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 35886000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Inventory: 3380158000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 3380158000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 7668878000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 7668878000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -39620000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 57818000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 57818000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 2225412000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 2225412000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 129762000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 129762000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 129762000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 129762000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 35433000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 35433000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 294749000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 294749000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 0.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Net Debt: 339726000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 339726000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Net Income: 385997000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Net Income: 14810000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 385997000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 14810000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 380595000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 9407000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Net Income Extraordinary: 5403000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Net Income Extraordinary: 5403000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 380594000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 9407000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 380594000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 9407000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 405844000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 385998000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 14810000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Net Interest Income: -104838000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -13659000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 2643000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 121545000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: 81111000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -104838000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -13659000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Net Other Investing Changes: 1000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Net PPE: 2861055000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 2861055000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -78150000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 40434000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 6372050000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 6372050000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 0.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 0.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 35433000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 35433000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 12863000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 12863000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 543441000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 42750000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Normalized Income: 380594000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 9407000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 175814000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Operating Income: 459822000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Operating Income: -9280000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Operating Revenue: 3649082000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 519677000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 19004000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 19004000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Other Cash Adjustment Outside Changein Cash: -3000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 1000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 1000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 97916000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 97916000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 71822000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 71822000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: 65648000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 48000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 48000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: -1000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: -1000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 45458000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 38619000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 300866000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 163020000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Other Payable: 507488000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 507488000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Other Properties: 48197000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 48197000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 15920000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 15920000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 1664913000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 1664913000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Other Special Charges: 4540000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Payables: 1309878000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Payables: 1309878000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Pension And Employee Benefit Expense: 5063000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 8470000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 8470000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 1669203000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 1669203000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Pretax Income: 400442000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 15680000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: -5403000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -79204000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 118919000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 118919000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 1355478000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 176785000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 38161000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 13411000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 31101000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 145062000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Research And Development: 124172000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 3713000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 3713000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 4762734000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 4762734000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 2643000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 1054000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 1169717000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 112326000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 1169717000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Selling General And Administration: 112326000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Share Issued: 19004000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 19004000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Special Income Charges: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 6443872000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 6443872000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 6372050000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 6372050000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Tax Provision: 19847000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 6273000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.05
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.30
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 56788000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 56788000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -10839000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Total Assets: 10262074000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 10262074000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 6573634000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 6573634000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Total Debt: 1225006000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 1225006000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 6443872000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 6443872000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Total Expenses: 3189260000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 528957000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 3818202000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 3818202000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 3361996000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 3361996000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 165194000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 165194000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 7490000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 3900000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 3900000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Trading Securities: 57281000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Trading Securities: 57281000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Work In Process: 122556000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 122556000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Working Capital: 3247070000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 3247070000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Write Off: 2159000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 1065673000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 2837001000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 19040398.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 19.58
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 1398239000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 9750000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 9750000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 19040398.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 19.58
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 372811000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — EBIT: 390735000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — EBITDA: 400485000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 1438762000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 31961000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 31961000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Net Income: 372811000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 372811000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 352177000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Net Income Extraordinary: 20634000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 352177000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 352177000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 372811000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -31961000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -31961000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 400485000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 352177000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Operating Income: 373089000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 2837001000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 17645000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 93005000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 358774000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 1398239000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 9750000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 866991000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Selling General And Administration: 866991000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 6597000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.02
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 2463912000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 216275000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 438496000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 693237000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 1793528000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 188581000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 19666429.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 1.40
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 7424000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 1588689000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 6798534000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 171055000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 7063906000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 1406269000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 1406269000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 3166138000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 6836000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 9872000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 9872000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 19666429.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 1.40
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 27533000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — EBIT: 91149000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — EBITDA: 101021000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 64342000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 2430823000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 267441000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 36571000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 36571000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 3079643000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 8346822000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 188581000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 142019000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 142019000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 35062000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Minority Interest: 0.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 1540864000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Net Income: 27533000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 27533000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 48167000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Net Income Extraordinary: -20634000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 48167000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 48167000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 27533000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -36571000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -36571000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 2430823000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 6734192000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 0.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 80387000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 29956771.01
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Operating Income: 51166000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 438496000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 19004000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 31650000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 1042888000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 64342000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 394101000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 19349000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 53255000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 2430823000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Receivables: 495289000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 1581265000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Payables: 710145000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 54578000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 171055000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 9872000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 49271000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Selling General And Administration: 49271000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 19004000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 20634000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 6798534000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 6734192000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 2423771.01
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 6411000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.12
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 75107000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 10141753000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 6940553000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 1548288000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 6798534000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 387330000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 3343219000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 3077847000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 177081000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 16908000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 20634000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 20634000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 3897768000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 345836000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 659590000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 19105952.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 0.84
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 287767000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 9753000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 9753000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 19105952.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.84
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 16049000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — EBIT: 70202000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — EBITDA: 79955000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 371823000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 45425000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 45425000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Net Income: 16049000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 16049000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 16049000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Net Income Extraordinary: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 16049000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 16049000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 16049000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -45425000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -45425000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 53095000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Normalized Income: -1349237.88
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Operating Income: 25987000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 659590000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 17356000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 98660000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 24777000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 287767000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 9753000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 121371000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Selling General And Administration: 121371000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: 26860000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 9461762.12
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 8728000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.35
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 633603000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: 26860000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 26860000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — +Operating Expense: 1951229000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 323446000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — +Total Revenue: 4451015000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 515928000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 1311206000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 1311206000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 854148000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 854148000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 265111000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 265111000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 19842850.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 19004000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Basic EPS: 20.98
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Basic EPS: -0.79
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 888992000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -30051000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 759953000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 759953000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 2394202000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 2394202000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -38008000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -1125317000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: 15458000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: -349769000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Change In Payable: 516370000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Change In Receivables: 251555000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -691703000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -129038000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Common Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 6804588000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 6804588000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 205000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 205000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 2015041000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 157980000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Current Assets: 7788634000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 7788634000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Current Debt: 1211793000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 1211793000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 1211793000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 1211793000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 3946952000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 3946952000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 8545000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 8545000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Depreciation: 39642000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 39642000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 39642000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 10268000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 39642000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 10268000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 19842850.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 19004000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Diluted EPS: 20.98
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.79
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 416303000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -89000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — EBIT: 622919000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — EBIT: 70835000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — EBITDA: 662561000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — EBITDA: 81103000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — End Cash Position: 759953000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -37882000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: -155783000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: -22000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 55856000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 55856000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 2438220000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 2438220000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Gross Profit: 2435974000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 357948000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Interest Expense: 159884000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 45928000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 159884000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 45928000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -159884000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 65265000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Inventory: 4505476000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 4505476000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 8189603000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 8189603000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: 34576000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 265111000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 265111000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 173222000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 173222000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 173222000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 173222000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 49468000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 49468000.00
NATHBIOGEN.NS balance_sheet (annual, 2026-03-31) — Net Debt: 625062000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 625062000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Net Income: 416303000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Net Income: -89000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 416303000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -89000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 416303000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -89000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Net Income Extraordinary: 0.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Net Income Extraordinary: 0.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 416303000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -89000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 416303000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -89000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 463034000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 416303000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -89000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Net Interest Income: -159884000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -45928000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -1201000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: 160010000.00
NATHBIOGEN.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: 43460000.00
NATHBIOGEN.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -159884000.00
NATHBIOGEN.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -45928000.00